Company intelligence / Profile preview
Aronora, Inc.
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
Aronora has developed a pipeline of first-in-class biologic drug candidates for life-threatening blood diseases. Their lead candidate AB002 (E-WE thrombin) is in Phase 2 trials for safe anticoagulation in heparin-intolerant end-stage renal disease patients on dialysis. The company’s approach aims to prevent pathological blood clots without the bleeding risks associated with current antithrombotics. AB002 has received FDA Fast Track designation and early clinical data have been presented at major hematology meetings.[1][7]
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Recombinant monoclonal antibodiesProtein C activator enzymes (biologics)Enzymes[1][5][6]
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Aronora, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aronora, Inc..